Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPezaro, Carmelen
dc.contributor.authorDavis, Ian Den
dc.identifier.citationCurrent Medicinal Chemistry; 15(12): 1166-74en
dc.description.abstractThe management of renal cell carcinoma (RCC) has undergone rapid and radical evolution over the last few years. An improved understanding of the underlying biology of RCC has led to the approval of several new therapies directed against specific and relevant biological targets, so-called "targeted therapies." These highly effective treatments are now entering routine use, however many questions still remain as to how best to use these agents and integrate them into the broader therapeutic armamentarium. This review summarizes the major published clinical trials of the new agents, discusses the controversies and research questions that have arisen as a result, and considers some of the issues that remain.en
dc.subject.otherAngiogenesis Inhibitors.therapeutic useen
dc.subject.otherAntineoplastic Agents.therapeutic useen
dc.subject.otherCarcinoma, Renal Cell.blood supply.drug therapyen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherKidney Neoplasms.blood supply.drug therapyen
dc.subject.otherReceptor, Epidermal Growth Factor.drug effectsen
dc.subject.otherRegional Blood Flow.drug effectsen
dc.subject.otherSignal Transduction.drug effectsen
dc.subject.otherVascular Endothelial Growth Factor A.drug effectsen
dc.titleTargeted therapies in the treatment of renal cell carcinoma.en
dc.typeJournal Articleen
dc.identifier.journaltitleCurrent medicinal chemistryen
dc.identifier.affiliationLudwig Institute Oncology Unit, Austin Health, Heidelberg, Victoria, Australiaen
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.